RATIONALE: Genetic testing for Long QT Syndrome is now a standard and integral component of clinical cardiology. A major obstacle to the interpretation of genetic findings is the lack of robust functional assays to determine the pathogenicity of identified gene variants in a high-throughput manner. OBJECTIVE: The goal of this study was to design and test a high-throughput in vivo cardiac assay to distinguish between disease-causing and benign KCNH2 (hERG1) variants, using the zebrafish as a model organism. METHODS AND RESULTS: We tested the ability of previously characterized Long QT Syndrome hERG1 mutations and polymorphisms to restore normal repolarization in the kcnh2-knockdown embryonic zebrafish. The cardiac assay correctly identified a benign variant in 9 of 10 cases (negative predictive value 90%), whereas correctly identifying a disease-causing variant in 39/39 cases (positive predictive value 100%). CONCLUSIONS: The in vivo zebrafish cardiac assay approaches the accuracy of the current benchmark in vitro assay for the detection of disease-causing mutations, and is far superior in terms of throughput rate. Together with emerging algorithms for interpreting a positive long QT syndrome genetic test, the zebrafish cardiac assay provides an additional tool for the final determination of pathogenicity of gene variants identified in long QT syndrome genetic screening.
RATIONALE: Genetic testing for Long QT Syndrome is now a standard and integral component of clinical cardiology. A major obstacle to the interpretation of genetic findings is the lack of robust functional assays to determine the pathogenicity of identified gene variants in a high-throughput manner. OBJECTIVE: The goal of this study was to design and test a high-throughput in vivo cardiac assay to distinguish between disease-causing and benign KCNH2 (hERG1) variants, using the zebrafish as a model organism. METHODS AND RESULTS: We tested the ability of previously characterized Long QT SyndromehERG1 mutations and polymorphisms to restore normal repolarization in the kcnh2-knockdown embryonic zebrafish. The cardiac assay correctly identified a benign variant in 9 of 10 cases (negative predictive value 90%), whereas correctly identifying a disease-causing variant in 39/39 cases (positive predictive value 100%). CONCLUSIONS: The in vivo zebrafish cardiac assay approaches the accuracy of the current benchmark in vitro assay for the detection of disease-causing mutations, and is far superior in terms of throughput rate. Together with emerging algorithms for interpreting a positive long QT syndrome genetic test, the zebrafish cardiac assay provides an additional tool for the final determination of pathogenicity of gene variants identified in long QT syndrome genetic screening.
Authors: Euan A Ashley; Ray E Hershberger; Colleen Caleshu; Patrick T Ellinor; Joe G N Garcia; David M Herrington; Carolyn Y Ho; Julie A Johnson; Steven J Kittner; Calum A Macrae; Gia Mudd-Martin; Daniel J Rader; Dan M Roden; Derek Scholes; Frank W Sellke; Jeffrey A Towbin; Jennifer Van Eyk; Bradford B Worrall Journal: Circulation Date: 2012-05-29 Impact factor: 29.690
Authors: Corey L Anderson; Brian P Delisle; Blake D Anson; Jennifer A Kilby; Melissa L Will; David J Tester; Qiuming Gong; Zhengfeng Zhou; Michael J Ackerman; Craig T January Journal: Circulation Date: 2006-01-24 Impact factor: 29.690
Authors: Michael J Ackerman; Silvia G Priori; Stephan Willems; Charles Berul; Ramon Brugada; Hugh Calkins; A John Camm; Patrick T Ellinor; Michael Gollob; Robert Hamilton; Ray E Hershberger; Daniel P Judge; Hervè Le Marec; William J McKenna; Eric Schulze-Bahr; Chris Semsarian; Jeffrey A Towbin; Hugh Watkins; Arthur Wilde; Christian Wolpert; Douglas P Zipes Journal: Heart Rhythm Date: 2011-08 Impact factor: 6.343
Authors: Rima Arnaout; Tania Ferrer; Jan Huisken; Kenneth Spitzer; Didier Y R Stainier; Martin Tristani-Firouzi; Neil C Chi Journal: Proc Natl Acad Sci U S A Date: 2007-06-25 Impact factor: 11.205
Authors: Xianqin Zhang; Shenghan Chen; Li Zhang; Mugen Liu; Sharon Redfearn; Randall M Bryant; Carlos Oberti; G Michael Vincent; Qing K Wang Journal: BMC Med Genet Date: 2008-09-23 Impact factor: 2.103
Authors: Corey L Anderson; Saba Munawar; Louise Reilly; Timothy J Kamp; Craig T January; Brian P Delisle; Lee L Eckhardt Journal: Front Cardiovasc Med Date: 2022-07-04
Authors: Matthew D Perry; Chai Ann Ng; Kevin Phan; Erikka David; Kieran Steer; Mark J Hunter; Stefan A Mann; Mohammad Imtiaz; Adam P Hill; Ying Ke; Jamie I Vandenberg Journal: J Physiol Date: 2016-05-27 Impact factor: 5.182
Authors: Jarryd M Campbell; Katherine A Hartjes; Timothy J Nelson; Xiaolei Xu; Stephen C Ekker Journal: Circ Res Date: 2013-08-16 Impact factor: 17.367
Authors: Christina M Hull; Christine E Genge; Yuki Hobbs; Kaveh Rayani; Eric Lin; Marvin Gunawan; Sanam Shafaattalab; Glen F Tibbits; Tom W Claydon Journal: Am J Physiol Regul Integr Comp Physiol Date: 2019-10-30 Impact factor: 3.619
Authors: Jakob Gierten; Christian Pylatiuk; Omar T Hammouda; Christian Schock; Johannes Stegmaier; Joachim Wittbrodt; Jochen Gehrig; Felix Loosli Journal: Sci Rep Date: 2020-02-06 Impact factor: 4.379
Authors: Dominik S Westphal; Tobias Burkard; Alexander Moscu-Gregor; Roman Gebauer; Gabriele Hessling; Cordula M Wolf Journal: Mol Genet Genomic Med Date: 2020-05-08 Impact factor: 2.183